Results 21 to 30 of about 1,426 (171)
The Effect of Teprotumumab on Eyelid Position in Patients with Thyroid Eye Disease
Plastic and Reconstructive Surgery, Global Open, 2022 Summary:. Teprotumumab has been shown to improve proptosis and clinical activity scores (CAS) in patients with thyroid eye disease, but little has been published regarding its effects on eyelid retraction. The purpose of this work was to evaluate changes
Brittany A. Simmons, MD +3 more
doaj +1 more source
Journal of Medical Case Reports, 2022 Background Teprotumumab is a novel treatment that reduces inflammation and symptoms caused by thyroid eye disease. There are limited data on teprotumumab’s effect on intraocular pressure.
Matthew Chu +4 more
doaj +1 more source
An Update on Medical Management of Thyroid Eye Disease with Insights on Teprotumumab
Delhi Journal of Ophthalmology, 2023 Thyroid eye disease (TED) is a debilitating autoimmune condition. It occurs most commonly with the hyperthyroid state but can also be seen in euthyroid and hypothyroid states.
Smriti Dabas +2 more
doaj +1 more source
Teprotumumab: a disease modifying treatment for graves’ orbitopathy
Thyroid Research, 2020 Background On 21st January 2020, the FDA approved Tepezza (teprotumumab-trbw) for the treatment of active Graves’ orbitopathy (GO) in adults. This approval was based on positive results from two multinational randomised double-blind placebo-controlled ...
Michelle Ting, Daniel G. Ezra
doaj +1 more source
Teprotumumab in advanced reactivated thyroid eye disease
American Journal of Ophthalmology Case Reports, 2022 Purpose: To report the case of a patient with reactivated, refractory thyroid eye disease (TED) treated with teprotumumab. Observations: A 51-year-old female with a 16-year history of thyroid eye disease previously treated with orbital decompression and ...
Olivia T. Cheng, Dianne M. Schlachter
doaj +1 more source
Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity [PDF]
, 2023 CONTEXT: Early inflammatory thyroid eye disease (TED) can lead to symptomatic chronic disease, including disabling proptosis. Teprotumumab, an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, previously demonstrated efficacy in acute, high ...
Ugradar, Shoaib +12 more
core +1 more source
International Journal of Clinical Practice, 2023 In this study, we conducted a meta-analysis to assess the efficacy and safety of teprotumumab in treating thyroid eye disease. We searched the Cochrane Library, PubMed, and Embase databases from inception to May 25, 2022, and included all randomized ...
Fei Lin +5 more
doaj +1 more source
Facial and Eyelid Changes in Thyroid Eye Disease Are Reversed by Teprotumumab
Plastic and Reconstructive Surgery, Global Open, 2021 Background:. Thyroid eye disease (TED) causes orbital soft-tissue expansion. Recent studies have suggested that brow and temple changes may also occur. Teprotumumab, a monoclonal antibody to the insulin-like growth factor 1 receptor reduces soft-tissue ...
Shoaib Ugradar, MD +4 more
doaj +1 more source
Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma
Cancer Medicine, Volume 12, Issue 14, Page 15207-15216, July 2023., 2023 Abstract Background Ewing sarcoma (EWS) is an aggressive sarcoma with few treatment options for patients with relapsed disease. Cyclin‐dependent kinase 4 (CDK4) is a genomic vulnerability in EWS that is synergistic with IGF‐1R inhibition in preclinical studies.
David S. Shulman +14 more
wiley +1 more source
Thyroid dermopathy responds to teprotumumab therapy
Endocrinology, Diabetes & Metabolism Case Reports, 2022 Thyroid dermopathy is an uncommon manifestation of thyroid disease that impairs the quality of life in certain cases. Currently, the available treatments offer limited results and a chance of recurrence.
Ricaurte Crespo-Trevino +6 more
doaj +1 more source